Douglas Fearon

Douglas Fearon
Born Douglas Thomas Fearon
(1942-10-16) October 16, 1942[1]
Fields Immunology
Alma mater
Notable awards
Website
www.cruk.cam.ac.uk/research-groups/fearon-group

Douglas Thomas Fearon FRS FRCP FMedSci (born 16 October 1942)[1][2] is an American medical immunologist, who has been since 2003 Sheila Joan Smith Professor of Immunology at the University of Cambridge and a fellow of Trinity College, Cambridge.[3][4][5][6]

Awards and honours

Fearon was elected a Fellow of the Royal Society (FRS) in 1999 and is also member of the United States National Academy of Sciences.[3] His nomination for the Royal Society reads:

“ The research of Douglas T. Fearon has helped establish a unifying principle in immunology; namely, that the two systems of immunity, innate and acquired, are integrated. The former identifies antigens of microbial origin to bias the response of the latter to those antigens. The support this thesis, he has 1) determined how the alternative complement pathway of innate immunity attaches C3 to microbial antigens; 2) demonstrated that the attached C3 causes antigen to be orders of magnitude more potent in eliciting an acquired immune response; and 3) characterised the CR2/CD19 receptor complex of B lymphocytes that mediates the enhanced immunogenicity of C3-bearing antigens, and the counter-regulatory coreceptor, CD22, that suppresses the cellular response to antigen.[7] ”

References

  1. 1 2 3 FEARON, Prof. Douglas Thomas. Who's Who. 2015 (online Oxford University Press ed.). A & C Black, an imprint of Bloomsbury Publishing plc. (subscription required)
  2. ↑ "Douglas Fearon". Debretts.
  3. 1 2 Nuzzo, R. (2005). "Biography of Douglas T. Fearon". Proceedings of the National Academy of Sciences. 102 (21): 7415–7417. doi:10.1073/pnas.0502415102.
  4. ↑ Feig, C; Jones, J. O.; Kraman, M; Wells, R. J.; Deonarine, A; Chan, D. S.; Connell, C. M.; Roberts, E. W.; Zhao, Q; Caballero, O. L.; Teichmann, S. A.; Janowitz, T; Jodrell, D. I.; Tuveson, D. A.; Fearon, D. T. (2013). "Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer". Proceedings of the National Academy of Sciences. 110 (50): 20212–7. doi:10.1073/pnas.1320318110. PMC 3864274Freely accessible. PMID 24277834.
  5. ↑ Roberts, E. W.; Deonarine, A; Jones, J. O.; Denton, A. E.; Feig, C; Lyons, S. K.; Espeli, M; Kraman, M; McKenna, B; Wells, R. J.; Zhao, Q; Caballero, O. L.; Larder, R; Coll, A. P.; O'Rahilly, S; Brindle, K. M.; Teichmann, S. A.; Tuveson, D. A.; Fearon, D. T. (2013). "Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia". Journal of Experimental Medicine. 210 (6): 1137–51. doi:10.1084/jem.20122344. PMC 3674708Freely accessible. PMID 23712428.
  6. ↑ Fearon, D. T.; Locksley, R. M. (1996). "The instructive role of innate immunity in the acquired immune response". Science. 272 (5258): 50–3. doi:10.1126/science.272.5258.50. PMID 8600536.
  7. ↑ "EC/1999/15: Fearon, Douglas Thomas". London: The Royal Society. Archived from the original on 2015-04-05.
This article is issued from Wikipedia - version of the 11/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.